Valsartan recall expands to Mylan, Teva products
admin 28th November 2018 Uncategorised 0When a suspected carcinogen was detected by a U.S. drugmaker last summer in the API it had acquired to make blood pressure drugs, it first appeared to be another issue of tainted products produced in China. Since then, the FDA has learned the problem is much broader, with two of the largest generics drugmakers now recalling dozens of lots after Mylan found a suspected carcinogen in the API it produced.
More: Valsartan recall expands to Mylan, Teva products
Source: fierce